Recently, it was reported that Shenzhen Yangqi Medical Core Intelligent Technology Co.
, Ltd.
(hereinafter referred to as "Yangqi Medical Core") has obtained tens of millions of yuan in angel round financing
led by Yuansheng Venture Capital and co-invested by old shareholder Sequoia China Seed Fund.
It is understood that the capital raised will be used to develop and innovate intelligent medical devices and accelerate the landing of products, deepen nuclear medical scenarios, provide high-precision software and hardware integrated navigation systems and overall intelligent operating room solutions for radiotherapy, so that medical devices have intelligent eyes and brains, accurately control equipment operation and treatment, improve treatment effects and efficiency, and optimize patient experience
.
It is worth mentioning that Yangqi Medical Core was established in September 1021, and it has completed two rounds of financing
since its establishment.
Specifically, just over one month after its founding, the company received its first round of multi-million dollar financing
exclusively invested by Sequoia China Seed Fund in November.
After a few months, this round of financing
was obtained.
In fact, it can be seen from how long Yangqi Medical Core has been established for one year and has obtained two rounds of financing
.
Since the beginning of this year, the investment and financing boom in the medical and health field has actually been continuing
.
Data show that in the first half of the year, there were 632 investment and financing events in the medical and health field nationwide, and the disclosed investment and financing amount reached 115.
2 billion yuan.
Among them, medical devices in subdivided fields have attracted much capital attention, and the financing scale of tens of millions of yuan is not a few
.
It is reported that in addition to Yangqi Medical Core, in the past month, a large number of companies have also announced that they have obtained financing, which will accelerate product innovation and promotion
.
For example, on November 28, ZKANG Zhongke International Biotechnology Co.
, Ltd.
completed a series B financing
of nearly 100 million yuan.
According to the data, ZKS takes the outsourcing preclinical research evaluation services ("preclinical CRO") of biomedicine and medical devices as its main business, and the company provides a one-stop service platform
including safety evaluation research, pharmacological and pharmacodynamic research and pharmacokinetic research.
This round of financing is led by AstraZeneca CICC Medical Industry Fund, and the old shareholder Ji Shi Capital once again co-invested, the funds will be mainly used to promote the construction of key resources required for the preclinical evaluation of innovative drugs/devices and the development layout
of Hong Kong and international business.
Prior to this, Kangpai Medical Technology (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Kangpai Medical") has also completed a series A financing
of tens of millions of yuan jointly invested by Qianhang Capital and Boyong Investment.
The proceeds from this round of financing will be used to accelerate the commercialization of the company's existing breast cancer-related products at home and abroad, and promote the company's comprehensive layout
of advanced breast cancer prevention and treatment products.
According to the data, Kangpai Medical is a technology-based enterprise
focusing on the field of breast cancer screening, diagnosis and treatment equipment and serving the global market.
The core team is composed of overseas returnee experts and scholars, technical experts and industry professionals of international equipment manufacturers, and has domestic and foreign clinical expert consultant resources
.
In 2020, it launched the intraoperative specimen imaging system for breast cancer, which is mainly used for minimally invasive breast biopsy, surgery and pathological materials
.
In addition, Nanjing Siyuan Medical Technology Co.
, Ltd.
has recently completed tens of millions of yuan financing
.
This round of financing was led by its old shareholder Boyuan Capital, and followed by Taiyu Investment
.
All proceeds will be used for research and development, clinical and registration of new products
.
It is understood that Siyuan Medical is a scientific and technological innovation enterprise
of medical beauty products with biomedical polymer materials as the core, focusing on the research and development, production and sales of medical beauty raw materials and medical devices.
At present, Siyuan Medical has two core technology platforms: medical grade polycarbonate series biopolymer material product transformation platform and biomedical hydrogel crosslinking technology platform
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
